Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
October 22, 2024 - It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle. Tribute to Dr. Blagosklonny.
On July 22, 2024, Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry. In celebration of the new additions, we are excited to offer a special discount of 50% on all publication fees until the end of the year. Read the press release for further details.
On June 11, 2024, Impact Journals (Oncotarget's publisher) will sponsor Team Open Access in the Ride for Roswell annual cycling event to end cancer on Saturday, June 22, 2024. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, NY. Learn More.
May 30, 2024 - At the Society for Scholarly Publishing (SSP) 46th Annual Meeting, Impact Journals (Oncotarget’s publisher), received a "Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion.
February 22, 2024 - Oncotarget is a contributing sponsor at the International Centre for Genetic Engineering and Biotechnology (ICGEB) 19th International p53 Workshop from May 13–16, 2024, in Trieste, Italy. Learn More.
On June 1, 2023, at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, Impact Journals (Oncotarget's publisher), received a "Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn More.
On May 17, 2023, Impact Journals (Oncotarget's publisher) will sponsor Team Open Access in the Ride for Roswell annual cycling event to end cancer on Saturday, June 24, 2023. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, NY. Learn More.
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. Learn more.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more.
On June 2, 2022, at the Society for Scholarly Publishing (SSP) 44th Annual Meeting, Impact Journals, Oncotarget's publisher, received a "Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion. Learn more.
On June 25, 2022 – Impact Journals (Oncotarget's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, New York. Learn more.
June 1–3, 2022 – Impact Journals (Oncotarget's publisher) is a supporter and exhibitor at the Society for Scholarly Publishing (SSP) 44th Annual Meeting. We will be presenting our full scientific integrity process at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois. Learn more.
On March 28, 2022 – Impact Journals publishes scholarly journals in biomedical sciences with a focus on all areas of cancer and aging research. Impact Journals is participating as an exhibitor at the American Association for Cancer Research (AACR) 2022 annual meeting from April 8-13, 2022, in New Orleans, Louisiana. This year, the AACR conference is entitled, “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.”
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
On September 23, 2021, Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) launched a new web page showcasing the full Oncotarget Scientific Integrity Process.
The new page also showcasts a visual representation of the number of post-publication corrections and retractions by Oncotarget compared to the industry average between 2010 and 2021. As of September 23, 2021, Oncotarget’s rate of corrections/retractions is 2.87%. The industry average correction/retraction rate is 3.80%.
